|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Severe COVID-19 infections are believed to be triggered by an over-reaction of the immune system, known as a "cytokine storm" that result in hyperinflammation throughout the body, including the lungs, heart and brain. The cytokine storm exacerbates the person's breathing difficulties and can lead to potentially fatal acute respiratory distress syndrome (ARDS). Immunomodulatory and anti-inflammatory drugs can play a role in arresting a rapid escalation of symptoms. Quercetin, a flavonoid, is a known modulator of inflammatory response with strong anti-inflammatory capacities including: modulation of NF-kB transcription factor, inhibition of cytochines (e.g. TNF-α), inhibition of production of pro-inflammatory enzymes, such as cyclooxygenase (COX) and lipoxygenase (LOX), which catalyze the conversion of arachidonic acid to its metabolites. The combination of three crucial properties of Quercetin as antioxidant, anti-inflammatory and immunomodulatory makes it a potential candidate to support all unhealthy conditions where oxidative stress, inflammation and immunity are involved. The investigators believe that the bioavailable form of Quercetin (Quercetin Phytosome) can prevent the disease progression in people with COVID-19 infection and can lead to rapid symptoms improvement. The aim of this study is to investigate he adjuvant benefits of Quercetin Phytosome in patents with COVID-19. Patients with a diagnosis of COVID-19 and, due to moderate to severe symptoms, hospitalized, will be randomized to take tablets containing Quercetin Phytosome (QP) 500 mg, 2 times a day:1 tablet during the breakfast and 1 tablet during the dinner, as add-on to the standard therapy. The treatment will last for 30 days. The treated patients will be compared with an equal group not treated with QP but only with standard therapy. Survival time, symptoms and objective (inflammatory) parameters (see Detailed description) will be analyzed as outcomes.
Description: The survival time will be compared between the two groups.Measure: Survival time Time: During the 30 days treatment
Description: Length of hospital stay will be compared between the two groups.Measure: Length of stay in hospital Time: During the 30 days treatment
Description: The duration of the mechanical ventilation required will be compared between the two groups.Measure: Days of mechanical ventilation Time: During the 30 days treatment
Description: The blood parameters will be compared between the two groups.Measure: Blood parameters according to the protocol described above Time: Day 0,15,30
Description: The blood gas analysis will be compared between the two groups.Measure: Blood gas analysis Time: Days 0,7,15,30
Description: The radiological imaging will be compared between the two groups.Measure: Radiological imaging Time: Days 0,15,30
Description: The PaO2 will be compared between the two groups.Measure: PaO2 Time: Days 0,7,15,30
Description: The heart rate will be compared between the two groups.Measure: Heart rate Time: Days 0,7,15,30
Description: The respiratory rate will be compared between the two groups.Measure: Respiratory rate Time: Days 0, 7,15,30
Description: The Quality of life questionnaire will be compared between the two groups.Measure: Quality of life questionnaire Time: Days 0 and 30
Description: The number of dose of the other drugs used will be compared between the two groups.Measure: Number and dose of other drugs used Time: Days 15, 30
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports